17, 2025 /PRNewswire/ -- Novo Nordisk announced today that the US Food and Drug Administration (FDA) has approved Rybelsus , the only oral GLP-1 medication available, for reducing the risk of major adverse cardiovascular events (MACE) such as cardiovascular (CV) death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events, whether they've had a prior CV event or not (primary and secondary prevention)
This fulfills Farrell et al.s [64] recommendation for more participatory rather than participant-informed methods and designs in obesity research
Importantly, the FDA labeling does not list infertility as a known adverse effect of semaglutide
Some people find crackers or toast helpful, while others prefer fruit or yogurt
Medicines like Ozempic, Wegovy, and Mounjaro have revolutionised the way doctors treat obesity and diabetes